Compare Synchrony Financial (SYF) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synchrony Financial vs Zoetis Inc — how do they compare? Synchrony Financial trades at $77.79 (market cap $25.17B), while Zoetis Inc trades at $73.71 (market cap $30.29B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| SYF | ZTS | |
|---|---|---|
Market Cap | $25.17B | $30.29B |
Sector | Financials | Health |
52-Week High | $88.47 | $150.61 |
52-Week Low | $63.78 | $71.91 |
Dividend Yield | 1.76% | 2.89% |
Enterprise Value | — | $37.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synchrony Financial (SYF) trades at $78.62, down 1.63% on the day, with a neutral technical signal. The stock shows strong fundamentals, including a low P/E of 7.93 and a robust ROE of 22.23%, supported by three consecutive quarterly earnings beats. Recent developments include a strategic partnership with OpenAI to enhance AI-driven commerce, announced on August 17, 2026, and a dividend payment scheduled for August 17, 2026.
The outlook is positive, with a consensus price target of $87.33 suggesting 11% upside. Key opportunities include earnings momentum and AI innovation, while risks involve consumer credit deterioration and investing cash flow turning negative in 2026. Analyst sentiment is bullish, with 62.5% recommending buy.
Zoetis (ZTS) trades at $73.6, down 2.92% on the day, near its 52-week low amid bearish technical signals. The stock shows strong fundamentals with a P/E of 12, net margin of 27.69%, and consistent earnings beats, but faces headwinds from weak U.S. companion animal sales and reduced 2026 guidance. Recent news includes an FDA emergency use authorization for Simparica Trio and participation in healthcare conferences.
The outlook is mixed: valuation appears attractive with a consensus price target of $93.40, but near-term risks include competitive pressures and soft pet health demand. Long-term investors may find value in its profitability and market dominance, though volatility persists from sector challenges and investor sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
